ReviewMolecular neurobiology2017
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.
Review in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Neuromodulators of orbitofrontal cortex function: A review of endocannabinoid, neurotrophin, and cell adhesion systems.Neurobiology of disease · 2026Review
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Targeting the Gut-Brain Axis with Plant-Derived Essential Oils: Phytocannabinoids and Beyond.Nutrients · 2025Review
- Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication.European archives of psychiatry and clinical neuroscience · 2025Article
- Behavioral characterization of triple-hit schizophrenia-like Lisket rats derived from the Long Evans strain through acute and chronic behavioral tests.Frontiers in psychiatry · 2025Article
- Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.Pharmacological reports : PR · 2024Article
- Endocannabinoid levels in plasma and neurotransmitters in the brain: a preliminary report on patients with a psychotic disorder and healthy individuals.Psychological medicine · 2024Article
- The Role of Cannabis in the Development of Psychosis.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Review
- Membrane Lipids in Ultra-High-Risk Patients: Potential Predictive Biomarkers of Conversion to Psychosis.Nutrients · 2023Article
- Ketogenic Diet and Inflammation: Implications for Mood and Anxiety Disorders.Advances in experimental medicine and biology · 2023Review
- Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.Biomedicines · 2022Review
- Combinatorial approaches for treating neuropsychiatric social impairment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Review
- The Current and Potential Application of Medicinal Cannabis Products in Dentistry.Dentistry journal · 2021Review
- Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.Psychopharmacology · 2021Article
- The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders .Dialogues in clinical neuroscience · 2020Review
- Are CB2 Receptors a New Target for Schizophrenia Treatment?Frontiers in psychiatry · 2020Review
- The Endocannabinoid System May Modulate Sleep Disorders in Aging.Current neuropharmacology · 2020Review
- Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the ECS in schizophrenia and presenting some potential antipsychotic compounds that modulate this system. Findings from animal and human studies, and their implications for pharmacotherapy, will be integrated and discussed in this paper. A closer look will be given at the roles of the cannabinoid receptors type 1 (CB
Indexed as
Identifiers
26768595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.